HAYWARD, Calif., May 25, 2010 (BUSINESS WIRE) --Impax Laboratories, Inc.(NASDAQ: IPXL) held its 2010
Annual Meeting of Stockholders today in San Mateo, California. Impax
stockholders elected to a one-year term each of the seven nominees for
director named in the Company's proxy statement, approved the amendment
of the Company's Amended and Restated 2002 Equity Incentive Plan and
ratified the appointment of Grant Thornton LLP as independent auditors
for the fiscal year ending December 31, 2010.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. is a technology based specialty pharmaceutical
company applying its formulation expertise and drug delivery technology
to the development of controlled-release and specialty generics in
addition to the development of branded products. Impax markets its
generic products through its Global Pharmaceuticals division and markets
its branded products through the Impax Pharmaceuticals division.
Additionally, where strategically appropriate, Impax has developed
marketing partnerships to fully leverage its technology platform. Impax
Laboratories is headquartered in Hayward, California, and has a full
range of capabilities in its Hayward and Philadelphia facilities. For
more information, please visit the Company's Web site at: www.impaxlabs.com.
SOURCE: Impax Laboratories, Inc.
Impax Laboratories, Inc.
Mark Donohue
Sr. Director, Investor Relations and Corporate Communications
215-933-3526
www.impaxlabs.com